Evidence map›Paper›PMID 26961115›Full record

ArticleDiabetes2016

B-lymphocytes expressing an Ig specificity recognizing the pancreatic ß-cell autoantigen peripherin are potent contributors to type 1 diabetes development in NOD mice.

Caroline M Leeth, Jeremy Racine, Harold D Chapman, Berta Arpa, Jorge Carrillo, Jorge Carrascal, Qiming Wang, Jeremy Ratiu, Leire Egia-Mendikute, Estela Rosell-Mases and 3 more

Open access · bronzeAbstract read
In one paragraph

Article in Diabetes, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers.

0numbers the graph read from it
0cells of the map it votes in
18citing papers in PubMed
2.4field-weighted citation impact, top 11% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

18 citing papers in PubMed, 19 citations in OpenAlex.

  1. Review
  2. Advancing Animal Models of Human Type 1 Diabetes.Cold Spring Harbor perspectives in medicine · 2024
    Review
  3. Review
  4. Article
  5. The NOD Mouse Beyond Autoimmune Diabetes.Frontiers in immunology · 2022
    Review
  6. Review
  7. Article
  8. Review
  9. T Cells from NOD-Journal of immunology (Baltimore, Md. : 1950) · 2020
    Article
  10. Article
  11. Article
  12. Review
  13. Article
  14. Article
  15. Article
  16. Review
  17. Article
  18. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors at 5 institutions in 2 countries.

Caroline M LeethThe Jackson Laboratory, Bar Harbor, Maine, USA Department of Animal and Poultry Sciences, Virginia Tech, Blacksburg, Virginia, USA.
Jeremy RacineThe Jackson Laboratory, Bar Harbor, Maine, USA.
Harold D ChapmanThe Jackson Laboratory, Bar Harbor, Maine, USA.
Berta ArpaImmunology Unit, Department of Experimental Medicine, Faculty of Medicine, University of Lleida & IRBLleida, Lleida, Spain.
Jorge CarrilloImmunology Unit, Department of Experimental Medicine, Faculty of Medicine, University of Lleida & IRBLleida, Lleida, Spain.
Jorge CarrascalImmunology Unit, Department of Experimental Medicine, Faculty of Medicine, University of Lleida & IRBLleida, Lleida, Spain.
Qiming WangThe Jackson Laboratory, Bar Harbor, Maine, USA.
Jeremy RatiuThe Jackson Laboratory, Bar Harbor, Maine, USA.
Leire Egia-Mendikute
Estela Rosell-Mases
Thomas StratmannDepartment of Physiology and Immunology, Faculty of Biology, University of Barcelona, Spain.
Joan VerdaguerImmunology Unit, Department of Experimental Medicine, Faculty of Medicine, University of Lleida & IRBLleida, Lleida, Spain dave.serreze@jax.org joan.verdaguer@mex.udl.cat.
David V SerrezeThe Jackson Laboratory, Bar Harbor, Maine, USA dave.serreze@jax.org joan.verdaguer@mex.udl.cat.
Jackson Laboratory · USBiomedical Research Institute of Lleida · ESUniversitat de Lleida · ESUniversitat de Barcelona · ESVirginia Tech · US

Funding

Shared Resource ManagementP30CA034196 · NCI · JACKSON LABORATORY · PI Mark D ADAMS · 1985 to 2026
$61.9M
The Jackson Laboratory Center for Precision Genetics: From New Models to Novel TherapeuticsU54OD020351 · OD · JACKSON LABORATORY · PI BURGESS, ROBERT W. · 2015 to 2019
$10.2M
Diabetogenic Role of MHC Class I Alleles in NOD MiceR01DK046266 · NIDDK · JACKSON LABORATORY · PI SERREZE, DAVID V · 2000 to 2018
$7.2M
B-lymphocyte Targeting Therapies for Autoimmune DiabetesR01DK095735 · NIDDK · JACKSON LABORATORY · PI SERREZE, DAVID V · 2013 to 2025
$6.2M
Optimizing B-lymphocyte Therapeutic Targeting Strategies in Autoimmune DiabetesK08DK101735 · NIDDK · VIRGINIA POLYTECHNIC INST AND ST UNIV · PI LEETH, CAROLINE MCPHEE · 2014 to 2018
$652k
DIABETOGENIC ROLE OF H-2G7 CLASS I ALLELES IN NOD MICER29DK046266 · NIDDK · JACKSON LABORATORY · PI SERREZE, DAVID V. · 1993 to 1998
–
NCI NIH HHS P30 CA034196NIDDK NIH HHS K08 DK101735NIDDK NIH HHS R01 DK046266NIDDK NIH HHS R01 DK095735NIDDK NIH HHS R29 DK046266NIH HHS U54 OD020351
6 · The paper itself

Abstract

While the autoimmune destruction of pancreatic ß-cells underlying type 1 diabetes (1D) development is ultimately mediated by T-cells in NOD mice and also likely humans, B-lymphocytes play an additional key pathogenic role. It appears expression of plasma membrane bound immunoglobulin (Ig) molecules that efficiently capture ß-cell antigens allows autoreactive B-lymphocytes bypassing normal tolerance induction processes to be the subset of antigen presenting cells most efficiently activating diabetogenic T-cells. NOD mice transgenically expressing Ig molecules recognizing antigens that are (insulin) or not (hen egg lysozyme; HEL) expressed by ß-cells have proven useful in dissecting the developmental basis of diabetogenic B-lymphocytes. However, these transgenic Ig specificities were originally selected for their ability to recognize insulin or HEL as foreign, rather than autoantigens. Thus, we generated and characterized NOD mice transgenically expressing an Ig molecule representative of a large proportion of naturally occurring islet-infiltrating B-lymphocytes in NOD mice recognizing the neuronal antigen peripherin. Transgenic peripherin autoreactive B-lymphocytes infiltrate NOD pancreatic islets, acquire an activated proliferative phenotype, and potently support accelerated T1D development. These results support the concept of neuronal autoimmunity as a pathogenic feature of T1D, and targeting such responses could ultimately provide an effective disease intervention approach.

Identifiers

PMID26961115
PMCPMC4915583
OpenAlexW2300774782

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.